177
Views
6
CrossRef citations to date
0
Altmetric
Letter to the Editor

Fludarabine, Cyclophosphamide and Rituximab (FCR) induced pulmonary hypertension in Waldenström macroglobulinemia

, , , &
Pages 1209-1211 | Received 22 Jan 2008, Accepted 22 Feb 2008, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Michael McGee, Nicholas Whitehead, Jennifer Martin & Nicholas Collins. (2018) Drug-associated pulmonary arterial hypertension . Clinical Toxicology 56:9, pages 801-809.
Read now
Ron Ram, Isaac Ben-Bassat, Ofer Shpilberg, Aaron Polliack & Pia Raanani. (2009) The late adverse events of rituximab therapy – rare but there!. Leukemia & Lymphoma 50:7, pages 1083-1095.
Read now

Articles from other publishers (4)

Takatoshi Suzuki, Ichizo Tsujino, Wataru Harabayashi, Hideki Shima, Junichi Nakamura, Takahiro Sato, Masaru Suzuki, Yukari Takeda & Satohi Konno. (2023) Pulmonary arterial hypertension in an 80-year-old man with long-term use of cyclophosphamide. Respiratory Medicine Case Reports 44, pages 101867.
Crossref
O. D. Ostroumova, A. I. Listratov, A. I. Kochetkov, S. A. Bliznyuk, A. G. Komarova & D. A. Sychev. (2022) Drug-induced pulmonary artery hypertension. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice:1, pages 53-63.
Crossref
Hayat Memis, Anca Elena Balinisteanu, Mihaela Gaman, Diana Mihalcea & Dragos Vinereanu. (2022) Acute right heart failure in Waldenström macroglobulinemia: A case report. Romanian Journal of Cardiology 32:1, pages 35-40.
Crossref
Laura Beaumier, Sébastien Chanoine, Boubou Camara, Christophe Pison & Pierrick Bedouch. (2017) Alemtuzumab and de novo pulmonary arterial hypertension: A potential association?. The Journal of Heart and Lung Transplantation 36:3, pages 370-371.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.